I think this was the last English version.
Dear Sir or Madam,
I read with interest the article by Professor Gundersen on the problems of patient participation in research, giving the example of ME. Dr Gundersen is right that patients may support poor projects, and gives a good example. However, his second example (PACE) shows the dangers of the argument.
The PACE study, which claimed cognitive behavioral therapy and exercise therapy to be good for ME, did appear in a ‘top’ journal. But quality is content, not cover. The Lancet has already made two major blunders in recent years. PACE has received a lot of criticism, not just from patients, but also senior scientists who find the trial of such poor quality as to be uninterpretable. I am one of forty scientists who, co-ordinated by David Tuller, have written to the Lancet to indicate concerns.
Many of these scientists became aware of problems with the trial from analysis by patients - notably Thomas Kindlon. Patients are leading the agenda here. The study was ‘open’, or unblinded, and used subjective endpoints. Blinding is needed to avoid bias from subjectivity and this type of design is no longer held valid in other medical fields. (In simple terms, patients say what they think the therapist wants to hear.) PACE had objective endpoints but these showed no useful effect. There were many other problems, with changes in recruitment criteria, outcome assessments, and definition of ‘recovery’. Most strangely, patients were told which treatments were best and had a newsletter saying how satisfied some were with treatment – as if trying to bias the outcome.
Dr Gundersen suggests that a campaign from 11,000 people might not be in pursuit of truth, but are more people likely to have worse motives? Nobody profits from a critique of PACE. I am retired and simply interested in what may help patients. If patients have robust evidence for poor science I support them. People are rightly angry because PACE is being touted as a basis for care. The idea of an undeserved attack is, I think, a myth, from the supporters of PACE and the Lancet editor, who seems to have forgotten that critique is a basic right in science – in fact the lifeblood.
I applaud Dr Gundersen for raising a complex and difficult issue, but his example shows how easy it is to underestimate patients. In ME, they are way ahead. The Norwegian Government has made a good decision. Norway is already a champion for people with ME, in epidemiology and immunology. Free debate can be noisy, but there is nothing better to generate ideas.
Yours sincerely,
Jonathan CW Edwards
Professor Emeritus
Department of Medicine
University College London